Metabolic Syndrome, Protection Against Clinical Trial
Official title:
Effects of Nature and Forest Therapy in Patients With Metabolic Syndrome and Cardiovascular Risk Factors - a Randomized Controlled Trial
NCT number | NCT04781491 |
Other study ID # | Wald |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 27, 2022 |
Est. completion date | December 2024 |
The aim of this study is to investigate the effects of regular forest therapy under guidance of a licensed nature therapist on patients with metabolic syndrome and cardiovascular risks
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Definition of Metabolic Syndrome according to the International Diabetes Foundation (IDF): - waist circumference: at least 94 cm for men, at least 80 cm for women - plus at least two of the following risk factors: - fasting blood glucose levels of > 100 mg/dl (> 5.6 mmol/l) measured in blood plasma or diagnosed diabetes mellitus - elevated triglycerides > 150 mg/dl (> 1.7 mmol/l) or therapy already initiated to lower triglycerides - low HDL cholesterol: < 40 mg/dl (< 1.05 mmol/l) in men and < 50 mg/dl (< 1.25 mmol/l) in women or already initiated therapy to increase HDL - Hypertension (from > 130 mmHg systolic and > 85 mmHg diastolic) or already treated hypertension Exclusion Criteria: - Serious acute or chronic illnesses - Immobility or limitation of mobility due to orthopedic, neurological or other medical cause - Participation in another study - Serious mental illness - Pregnancy and lactation |
Country | Name | City | State |
---|---|---|---|
Germany | Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | - Blood count | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - Blood lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - Parameters of glucose metabolism (insulin, glucose, HbA1C, insulin sensitivity) | Laboratory parameters will be combined to report Diabetes status | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - liver function (GOT, GPT, GGT) | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - Inflammation: hs-CRP, IL-6 | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - IFN-gamma, tumor necrosis factor alpha | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - uric acid | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - Lymphocyte populations: T cells (CD3), B cells (CD19), NK cells (CD16). | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - T cell subpopulations: T helper cells (CD4), cytotoxic T cells (CD8), CD4/CD8 ratio. | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - ferritin | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - cumulative steroid hormone concentration of the last 2 months in a hair strand | Laboratory parameters | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | • Apparatus parameters | Body weight
abdominal girth blood pressure measurement (24h) will be combined to report metabolic syndrome |
Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | • Qualitative evaluation (focus group interviews) | - Semi-structured interviews and focus group discussions with 16 subjects of the intervention group. | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | • Heart rate variability and other parameters | - Digital tracking using "wearables": parameters of stress levels and activity and sleep patterns are measured objectively using a smartwatch (fitbit). Heart rate variability (RMSSD), pulse, activity duration, type, and intensity as well as sleep duration, sleep phases, steps, and calorie consumption are recorded. The aim is to test whether the activity and pulse tracking data provide information about the variance in quality of life data. Will be combined to report quality of life. | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | - bioelectrical impedance analysis (BIA) | Estimation of the body composition via bio-electrical impedance analysis (muscle mass in kg) | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Other | Heart Rate (HR) | 24h measuring by smartwatch | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Other | Heart Rate Variability (HRV) | 24h measuring by smartwatch | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Other | Interbeat Interval (IBI) | 24h measuring by smartwatch | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Other | Number of steps | 24h measuring by smartwatch | Date of inclusion (baseline), after 8 weeks, after 16 weeks | |
Primary | • Final sum score of cardiovascular risk profile (overweight, blood pressure, blood lipids, blood glucose) according to Wiley/Carrington | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks | ||
Secondary | • Perceived Stress Scale (PSS) | Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived•stress. Higher score meaning more stress | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Secondary | • Short Form 12 Health Survey (SF-12) | The Short Form (12) Health Survey is a 12-item, patient-reported survey of patient health.The World Health Organisation- Five Well-Being Index (WHO-5) is a short self-reported measure of current mental wellbeing. score ranging from 0-5 for each question, lower score meaning a better outcome. | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Secondary | • Physical complaints (B-LR - Beschwerden-Liste) | the Complaints List - (B-LR) is a self-assessment procedure for recording subjective impairment due to physical or general complaints, covering the entire spectrum from no complaints to severe impairment. Two parallel forms (B-LR and B-LR') are available, each consisting of 20 items, lower score meaning a better outcome | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Secondary | • Flourishing Scale (FS-D) | The Flourishing Scale is a brief 8-item summary measure of the respondent's self-perceived success in important areas such as relationships, self-esteem, purpose, and optimism. The scale provides a single psychological well-being score, ranging from 8-56, higher score meaning a better outcome | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Secondary | • Hospital Anxiety and Depression Scale (HADS) | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | ||
Secondary | • Mindfulness (Freiburger Fragebogen zur Achtsamkeit, FFA) | Assessing full scale, range 0-56, higher score meaning a better outcome | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Secondary | • General Self-Efficacy Short Scale (ASKU-Allgemeine Selbstwirksamkeit Kurzskala) | Measurement instrument for recording subjective competence expectations. Scale ranging from 1-5, higher score meaning a better outcome | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Secondary | • International Physical Activity Questionnaire (IPAQ) | The 31-item long form and the 9-item short form assess time spent on different activities. The short form records four types of physical activity: vigorous activity such as aerobics; moderate-intensity activity such as leisure cycling; walking, and sitting.
MET minutes represent the amount of energy expended carrying out physical activity. To get a continuous variable score from the IPAQ (MET minutes a week) we will consider walking to be 3.3 METS, moderate physical activity to be 4 METS and vigorous physical activity to be 8 METS; higher score meaning better outcome; range 0 to around 3000 MET minutes a week |
Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | |
Secondary | • Weekly query of the exercise practice by means of (online) diary | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks] | ||
Secondary | Subjective Vitality Scale state (SVS-G state) | Assessing full scale, range 1-80, higher score meaning a better outcome | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks | |
Secondary | Perceived Benefits of Nature Questionnaire (PBNQ) | Assessing full scale, range 1-7, lower score meaning a better outcome | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks | |
Secondary | Profile of Mood States (POMS) | Date of Inclusion (Baseline), after 8 weeks and after 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595669 -
Personalised Advice for the Prevention of Metabolic Syndrome
|
N/A | |
Completed |
NCT02078687 -
Growth, Risks of Allergy and Metabolic Syndrome in 6 Year Old Children Born Preterm Compared to Postdischarge Nutrition
|
N/A | |
Active, not recruiting |
NCT04053569 -
Grape Polyphenols and Metabolic Syndrome
|
N/A | |
Not yet recruiting |
NCT06377956 -
The Associations Between Gut Length, Gut Microbiota and Food Assimilation
|
||
Recruiting |
NCT05764473 -
Diet, Cardiometabolic Risk (CM) and Menopause Symptoms
|
N/A | |
Recruiting |
NCT04477590 -
Interactions of Medicine and Exercise With Meal Timing
|
N/A | |
Not yet recruiting |
NCT06437860 -
Nutritional Intervention for Sustaining Health (NURISH) Trial
|
N/A | |
Not yet recruiting |
NCT04815538 -
The Relationship Between Workplace Environment and Metabolic Syndrome in Different Industries
|
||
Completed |
NCT01925547 -
Micellar Curcumin and Metabolic Syndrome Biomarkers
|
Phase 2 | |
Recruiting |
NCT03994367 -
Animal and Plant Proteins and Glucose Metabolism
|
N/A | |
Recruiting |
NCT06099288 -
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
|
N/A | |
Active, not recruiting |
NCT04564586 -
Developing and Testing a Technology-Based Translation of the DPP to Address Prediabetes in a Primary Care Setting
|
N/A | |
Completed |
NCT05703438 -
The Effect of a Low-calorie Diet With Balanced Nutrition on Metabolic Syndrome
|
N/A |